I2W PHARMA PRIVATE LIMITED

Name

I2W PHARMA PRIVATE LIMITED

Legal name

I2W PHARMA PRIVATE LIMITED

Website

https://i2wpharma.com

Company type

Private

Founded year

2026

Operating status

Operating

Short description

I2W PHARMA PRIVATE LIMITED is an Indian-incorporated pharmaceutical entity whose specific products, customers, operating activities, and market position cannot be determined from available data, as its website displays only a verification placeholder page.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule API Process Development & Route Scouting (HLAGAHAA)

akta.pro secondary industries

Full-Line Pharmaceutical Wholesalers (HLAIAJAA), Generic ANDA/Regulatory Affairs & Submissions (HLAIABAJ)

Keywords

• Pharmaceutical manufacturing
• Generic medicines
• Drug formulations
• Active pharmaceutical ingredients
• Pharmaceutical distribution

GTM type

B2B

Offering type

Hardware or Manufacturing

Core offering

I2W PHARMA PRIVATE LIMITED's core offerings cannot be directly determined from available source data. The company's website (i2wpharma.com) displayed only a verification placeholder page during data collection, providing no product catalog, service description, or business activity details. Based on the "PHARMA" component of the corporate name, the company likely operates within the pharmaceutical industry, but specific products, therapeutic areas, or service lines are not evidenced.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Direct peers

• Laurus Labs: India-based API and generics manufacturer with strong small-molecule and process development focus. Comparable because the subject likely operates in the same small-molecule API space and would compete for similar contract development, scale-up, and supply customers.
• Granules India: Indian API + finished-dose generics manufacturer with vertically integrated operations. Comparable to a small Indian pharma private limited in business model (APIs, generics), customer set (regulated-market buyers), and the kind of scale-up/tech transfer execution path a small player must follow.
• Solara Active Pharma Sciences: India-headquartered pure-play API manufacturer carved out of a larger pharma group. Comparable as a smaller, India-based API-focused entity — a realistic scale and operational profile for a private Indian pharma limited.
• Divi's Laboratories: India-based, API-focused manufacturer with strong process development and scale-up capabilities. Comparable because the subject, if it operates in API process development (a common Indian pharma sub-segment), competes in the same talent pool, customer base (global generics), and regulatory environment.
• Aarti Drugs: Mid-sized Indian manufacturer focused on APIs and intermediates across therapeutic categories. Comparable as a representative Indian small/mid API player in scale and product mix to what the subject company plausibly is or aspires to be.

Broad incumbents

• Ipca Laboratories: Established Indian manufacturer of APIs and formulations with global reach. Comparable as an Indian pharma incumbent in the same API/generics value chain where the subject would have to compete or partner.
• Aurobindo Pharma: Large Indian API and generic finished-dose manufacturer with global regulatory approvals. Comparable to the subject because it represents the most likely operating model and scale benchmark for an India-domiciled 'Pharma Private Limited' API/generics company, and is the natural M&A/strategic counterparty.

Emerging players

• Sequent Scientific: India-based API manufacturer with a more focused therapeutic portfolio. Comparable as an Indian mid-tier API player; a useful reference point for the scale and capability set a smaller Indian pharma private limited could realistically achieve.

Market position

Strengths2 records

Weaknesses3 records

Key risks5 records

Key highlights1 record

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about I2W PHARMA PRIVATE LIMITED